CL2019001537A1 - New T-cell receptors and immune therapy that uses them. - Google Patents
New T-cell receptors and immune therapy that uses them.Info
- Publication number
- CL2019001537A1 CL2019001537A1 CL2019001537A CL2019001537A CL2019001537A1 CL 2019001537 A1 CL2019001537 A1 CL 2019001537A1 CL 2019001537 A CL2019001537 A CL 2019001537A CL 2019001537 A CL2019001537 A CL 2019001537A CL 2019001537 A1 CL2019001537 A1 CL 2019001537A1
- Authority
- CL
- Chile
- Prior art keywords
- constructions
- taa
- cell receptors
- antigen recognition
- recognition
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 3
- 238000009169 immunotherapy Methods 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 101100168911 Arabidopsis thaliana CUL4 gene Proteins 0.000 abstract 1
- 102000012698 DDB1 Human genes 0.000 abstract 1
- 102100025178 DDB1- and CUL4-associated factor 4-like protein 2 Human genes 0.000 abstract 1
- 101100168913 Dictyostelium discoideum culD gene Proteins 0.000 abstract 1
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 abstract 1
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 abstract 1
- 101000721255 Homo sapiens DDB1- and CUL4-associated factor 4-like protein 2 Proteins 0.000 abstract 1
- 101100168914 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pcu4 gene Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 101150077768 ddb1 gene Proteins 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000009258 tissue cross reactivity Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCIÓN SE RELACIONA CON CONSTRUCCIONES DE RECONOCIMIENTO DE ANTÍGENO CONTRA UN ANTÍGENO ASOCIADO A TUMOR (TAA) DERIVADO DE LA PROTEÍNA BLANCO 2 SIMILAR AL FACTOR 4 ASOCIADO CON DDB1 Y CUL4 (DCAF4L2). LA INVENCIÓN EN PARTICULAR PROVEE NUEVAS MOLÉCULAS BASADAS EN RECEPTORES DE CÉLULAS T (TCR) QUE SON SELECTIVAS Y ESPECIFICAS POR EL TAA DE LA INVENCIÓN. LOS TCR DE LA INVENCIÓN, Y LOS FRAGMENTOS DE UNIÓN A TAA DERIVADOS DE LOS MISMOS, SON ÚTILES PARA EL DIAGNÓSTICO, TRATAMIENTO Y PREVENCIÓN DE ENFERMEDADES CANCEROSAS QUE EXPRESAN TAA. ADEMÁS SE PROVEEN ÁCIDOS NUCLEICOS QUE CODIFICAN PARA LAS CONSTRUCCIONES DE RECONOCIMIENTO DE ANTÍGENO DE LA INVENCIÓN, VECTORES QUE COMPRENDEN ESTOS ÁCIDOS NUCLEICOS, CÉLULAS RECOMBINANTES QUE EXPRESAN LAS CONSTRUCCIONES DE RECONOCIMIENTO DE ANTÍGENO Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA INVENCIÓN.THE PRESENT INVENTION IS RELATED TO ANTIGEN RECOGNITION CONSTRUCTIONS AGAINST A TUMOR-ASSOCIATED ANTIGEN (TAA) DERIVED FROM WHITE PROTEIN 2 SIMILAR TO FACTOR 4 ASSOCIATED WITH DDB1 AND CUL4 (DCAF4L2). THE INVENTION IN PARTICULAR PROVIDES NEW MOLECULES BASED ON T-CELL RECEPTORS (TCR) THAT ARE SELECTIVE AND SPECIFIC BY THE TAA OF THE INVENTION. THE TCRs OF THE INVENTION, AND THE TAA BINDING FRAGMENTS DERIVED THEREOF, ARE USEFUL FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER DISEASES THAT EXPRESS TAA. IN ADDITION, NUCLEIC ACIDS ARE PROVIDED THAT CODE FOR THE ANTIGEN RECOGNITION CONSTRUCTIONS OF THE INVENTION, VECTORS THAT INCLUDE THESE NUCLEIC ACIDS, RECOMBINANT CELLS THAT EXPRESS THE CONSTRUCTIONS OF CONSTRUCTION OF THE RECOGNITION OF ANTIGEN RECOGNITION AND COMPOSITION CONSTRUCTIONS.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431580P | 2016-12-08 | 2016-12-08 | |
| DE102016123859.7A DE102016123859B3 (en) | 2016-12-08 | 2016-12-08 | New T cell receptors and their use in immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001537A1 true CL2019001537A1 (en) | 2019-10-11 |
Family
ID=67874111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001537A CL2019001537A1 (en) | 2016-12-08 | 2019-06-05 | New T-cell receptors and immune therapy that uses them. |
Country Status (6)
| Country | Link |
|---|---|
| CL (1) | CL2019001537A1 (en) |
| CO (1) | CO2019006926A2 (en) |
| IL (1) | IL267131A (en) |
| MY (1) | MY196025A (en) |
| NZ (1) | NZ754366A (en) |
| PH (1) | PH12019501263A1 (en) |
-
2017
- 2017-12-07 NZ NZ754366A patent/NZ754366A/en not_active IP Right Cessation
- 2017-12-07 MY MYPI2019003103A patent/MY196025A/en unknown
-
2019
- 2019-06-05 CL CL2019001537A patent/CL2019001537A1/en unknown
- 2019-06-05 IL IL267131A patent/IL267131A/en unknown
- 2019-06-06 PH PH12019501263A patent/PH12019501263A1/en unknown
- 2019-06-27 CO CONC2019/0006926A patent/CO2019006926A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019006926A2 (en) | 2019-09-18 |
| MY196025A (en) | 2023-03-07 |
| IL267131A (en) | 2019-08-29 |
| NZ754366A (en) | 2022-02-25 |
| PH12019501263A1 (en) | 2020-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019006727A (en) | NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USES THEM. | |
| CL2019001535A1 (en) | New T-cell receptors and immune therapy that uses them. | |
| MX2019006724A (en) | NEW T-CELL RECEPTORS AND IMMUNE THERAPY THAT USES THEM. | |
| CL2020001181A1 (en) | New genetically modified T-cell receptors and immune therapies using them. | |
| EA201992131A1 (en) | HIGH-AFFINE SPECIFIC TO MAGE-A1 TCR AND THEIR APPLICATION | |
| MX395287B (en) | NEW T LYMPHOCYTE RECEPTORS AND IMMUNOTHERAPY BASED ON THEIR USE. | |
| BR112019024654A2 (en) | binding protein nkg2d, cd16 and ror1 or ror2 | |
| BR112017016336A2 (en) | single agonist binding proteins? | |
| MX2022000012A (en) | PREDICTION OF USEFUL CELL EPITOPES FOR VACCINATION. | |
| CO2019003951A2 (en) | CD123 binding proteins and related compositions and methods | |
| MY205262A (en) | Novel t cell receptors and immune therapy using the same | |
| BR112017007093A2 (en) | compositions and methods of use for enhancing immune response and cancer therapy | |
| JOP20220079A1 (en) | Multi-specific binding proteins for cancer treatment | |
| EA201690868A1 (en) | PERSONALIZED IMMUNOTHERAPY OF SEVERAL TYPES OF NEURAL TUMORS AND TUMORS OF THE BRAIN | |
| EA201891459A1 (en) | NEW GENERATION OF ANTIGENSPECIFIC TCR | |
| BR112018006006A2 (en) | antigen receptors, peptide chains, recombinant cells, methods for producing a cell expressing an antigen receptor and for treating a disease, nucleic acids and pharmaceutical composition | |
| MX2020001287A (en) | Braf-specific tcrs and uses thereof. | |
| EA202192252A1 (en) | HIGHLY AVIATED WT1 T-CELL RECEPTORS AND THEIR APPLICATIONS | |
| CL2019001537A1 (en) | New T-cell receptors and immune therapy that uses them. | |
| EA202090712A1 (en) | NEW GENETIC ENGINEERED T-CELL RECEPTORS AND IMMUNE THERAPY WITH THEIR USE | |
| EA201992002A1 (en) | T-CELL RECEPTORS AND IMMUNE THERAPY OF PRAME-POSITIVE CANCER DISEASES WITH THEIR APPLICATION | |
| AR110682A1 (en) | T-CELL RECEIVERS AND IMMUNE THERAPY USING THEM | |
| EA201991139A1 (en) | NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION | |
| EA201990488A1 (en) | NEW T-CELL RECEPTORS AND IMMUNOTHERAPY WITH THEIR APPLICATION | |
| EA201991181A1 (en) | PSMA-TARGETED TRANSPECIFIC PROTEINS AND WAYS OF THEIR APPLICATION |